Intergroupe Francophone du Myelome (IFM) Phase III Study (IFM 2005 02) Evaluating Treatment with Continuous REVLIMIDÂ® in Patients with Multiple Myeloma Following Autologous Stem Cell Transplant Meets Primary Endpoint